MINDHUNTER – PHENYLPIRACETAM / ANIRACETAM / ALPHA-GPC – Nootropic Supplement

The formula that combines phenylpiracetam, aniracetam and Alpha-GPC is interesting not only pharmacologically. Its three ingredients belong to two different regulatory groups — one has assessed status as a food ingredient, the other two are not authorized as either food or medicine in the European Union. This distinction determines how they may legally be described, and that’s why we start with it.

The article describes the mechanisms of the three components and the state of evidence for each of them separately. It does not contain doses, frequency of use or combination patterns.

Status information. Phenylpiracetam and aniracetam are not authorized as food ingredients or registered as medicinal products in the European Union. Material containing these compounds is not a dietary supplement and is not described as such. Phenylpiracetam is also on the WADA Prohibited List. Content intended for adults.

Three ingredients, two regulatory groups

This is the most important distinction in the entire article and at the same time most often omitted in descriptions of this type of formulas.

Practical consequence: presence in one capsule does not equal the status of the ingredients. Alpha-GPC remains a food ingredient with an assessed profile regardless of what it is combined with, and phenylpiracetam remains an unauthorized and prohibited substance in sport. A full map of the legal status of the entire category can be found in our material about nootropic substances.

Phenylpiracetam

Origin and structure

Phenylpiracetam is a derivative of piracetam with an additional phenyl ring. It was developed in the 1980s in a Soviet research program, and its pharmacological characterization as a “new phenyl analogue of piracetam” was published in 1983 (Bobkow et al., 1983, PMID 6403074). It operates under the international name as fonturacetam, historically also known as carphedon. It is still a registered medicinal product in Russia, which explains why much of the clinical literature regarding it is in Russian and is less accessible for independent verification.

The addition of a phenyl ring changed the properties of the molecule significantly: it increased the lipophilicity, and with it the penetration into the central nervous system, and gave it a profile different from that of the parent piracetam. The pharmacology of the entire family is described in reviews on piracetam and related compounds (Gouliaev and Senning, 1994, PMID 8061686), (Malykh and Sadaie, 2010, PMID 20166767).

Mechanism – inhibition of the dopamine transporter

The best documented mechanism of phenylpiracetam is its action on the dopamine transporter (DAT). Inhibition of this transporter reduces the reuptake of dopamine from the synaptic cleft, prolonging its signaling. This is a mechanism common to classic stimulants and explains why the compound was included in the S6 category of the Prohibited List, and not in the group of classic nootropics as defined by Giurgea.

Precision as to the source is important. Neuroprotective and anti-inflammatory activity was described in the study regarding R-phenylpiracetam – i.e. a single enantiomer, not a racemic mixture – in models of inflammation in mice (Zvejniece et al., 2020, PMID 32279140). Enantiomers of the same molecule may differ in activity, and the mouse model is not a clinical indication. Transferring these observations directly to the racemic preparation used by humans is a simplification.

What can and cannot be said about the effects

There are a number of claims about phenylpiracetam in circulation, the basis of which does not stand up to scrutiny. We are organizing them because it is more honest than repeating:

• Comparisons with methylphenidate and amphetamine appear in materials referring to the patent application. The patent application is not a peer-reviewed publication and does not constitute evidence of effectiveness.
• Summaries based on user surveys — including surveys from online forums — are not clinical data. They have no control group, no blinding, and no verification of what was actually taken.
• Claiming a “safer alternative” to modafinil is not supported by comparative research. Modafinil is a medicinal product with an established safety profile; phenylpiracetam does not have such a profile in the European Union because it has not undergone registration evaluation.

What can be said: the mechanism of influence on the dopamine transporter and activity in animal models have been described. For the population of healthy adults in the European Union, there is no data from studies meeting registration standards.

Aniracetam

Mechanism – modulation of AMPA receptors

Aniracetam is a modulator of AMPA receptors involved in glutamatergic transmission. It does not stimulate these receptors directly, but changes their response to glutamate — reducing the rate of desensitization, i.e. loss of sensitivity with repeated stimulation. This mechanism has been characterized on recombinant receptors (Johansen et al., 1995, PMID 7476926), and the pharmacological profile of the compound is summarized in a review (Nakamura, 2002, PMID 12070527).

The difference from direct stimulation is important: the modulator only acts where the signal is already present, and in this sense it enhances existing transmission, rather than triggering it from scratch.

Neurotrophic theme

Positive modulation of AMPA receptors is associated with increased expression of neurotrophic factors – this has been shown for hippocampal and cortical neurons (Lauterborn et al., 2000, PMID 10627576). These are cell culture observations, not clinical data; describe the possible direction of action of a class of compounds, not the effect in humans.

Human data

Human pharmacokinetic data exist for Aniracetam: in a study in healthy volunteers the pharmacokinetics and bioequivalence after a single administration was assessed (Tian et al., 2008, PMID 19025058). This is a study describing the behavior of a compound in the body, not its effect on cognitive functions.

Aniracetam differs from piracetam in solubility – it is a lipophilic compound, while piracetam dissolves in water. Lipophilicity determines the method of absorption and the fact that the presence of fat in the gastrointestinal tract affects the availability of the compound.

Alpha-GPC in this formula

Alpha-GPC has a different function than the other two ingredients: it is a choline precursor, i.e. it provides a substrate for the synthesis of acetylcholine. The compound profile is summarized in the review (Traini et al., 2013, PMID 24156263), and its effect on physical and psychomotor performance parameters was studied in humans (Marcus et al., 2017, PMID 29042830).

We discuss the mechanism and regulatory status of this ingredient in detail in a separate Alpha-GPC monograph – here we are only interested in its role as an element of the formula.

Why are racetams combined with a choline donor

The justification is mechanistic. Racetams have been reported to increase acetylcholine utilization – the relationship between this class of compounds and the cholinergic system is discussed in the literature review (Pepeu and Spignoli, 1989, PMID 2694231). Since increased use increases the demand for a substrate, the provision of a choline precursor is intended to cover this demand.

However, this is mechanistic justification, not a study result. There have been no studies evaluating this particular combination of three ingredients for effectiveness or safety. The inference “mechanism A plus mechanism B gives the effect A+B” is not a rule in pharmacology.

Legal status and anti-doping notice

Phenylpiracetam — under the international name fonturacetam, historically carphedon – is on the WADA Prohibited List in the category S6 (stimulants), in the section regarding non-specific stimulants. It has been there since 1998. Anti-doping rules are not limited to professionals: in Poland, the Prohibited List is in force through the Polish Anti-Doping Agency (POLADA), and amateur competitors taking part in competitions covered by these rules are also subject to control. A general clause applies – failure to mention a compound by name does not mean approval, because the ban also covers substances with a similar structure or similar biological effect. The current status should be verified each time in the current version of the List.

The doping potential of unauthorized ingredients in nootropic preparations, along with their regulatory status in various jurisdictions, is discussed in a review dedicated to this category (Jędrejko et al., 2023, PMID 37357012).

What is actually in the product

In the analysis of products sold as preparations supporting cognitive functions, researchers detected five unapproved medicinal substances, in some cases in amounts different from those declared, and in others without declaration on the label (Cohen et al., 2021, PMID 34484905). For a competitor subject to anti-doping control, this means the risk of violating the rules with a substance that he did not consciously choose. The identity of the material is determined by the analytical documentation of the batch, not the name on the package.

What the data do not show

• It does not show the result for this particular combination. No studies have been conducted to evaluate the combination of phenylpiracetam, aniracetam and Alpha-GPC.
• It does not show the safety profile of phenylpiracetam or aniracetam in the EU. None of them have undergone registration evaluation, so no such profile has been established.
• It does not show cognitive effects of aniracetam in humans. Available human data are related to pharmacokinetics, not performance on cognitive tasks.
• It does not show superiority over registered substances. Comparative studies with modafinil or other drugs have not been performed.

Frequently asked questions

Do all three ingredients have the same legal status?

No. Alpha-GPC is an EFSA assessed food ingredient, while phenylpiracetam and aniracetam are not authorized as food or registered as medicines in the European Union. Combining them in one product does not change the status of either of them.

Is phenylpiracetam banned in sports?

Yes. It has been on the WADA Prohibited List in category S6 (stimulants), under the name fonturacetam, since 1998. Aniracetam is not mentioned by name, but this does not exclude it from the clause covering substances with similar effects.

What is the difference between aniracetam and piracetam?

Aniracetam is a lipophilic compound, while piracetam dissolves in water – which results in differences in absorption. They also differ in the described mechanism: modulation of AMPA receptors has been documented for aniracetam.

Do user reports prove effectiveness?

No. Surveys and reports of feelings do not have a control group, blinding or verification of the composition of the preparation used. They do not replace controlled studies and are not cited as evidence in this article.

Why does the article not provide doses or frequency of use?

Because there is no established dosage for phenylpiracetam and aniracetam in the European Union – establishing one requires a registration process that these compounds have not undergone.

Summary

The formula combining Phenylpiracetam, Aniracetam and Alpha-GPC combines ingredients with three different mechanisms and two different regulatory statuses. Phenylpiracetam, or fonturacetam, is a derivative of piracetam developed in the 1980s that works by inhibiting the dopamine transporter – a mechanism shared with stimulants, which is why the compound has been on the WADA Prohibited List in category S6 since 1998. Aniracetam is a modulator of AMPA receptors, reducing the rate of their desensitization; pharmacokinetic, not cognitive, data are available for humans. Alpha-GPC acts as a choline precursor and is the only ingredient that has been assessed as a food ingredient. The combination of a racetam with a choline donor is based on mechanistic justification, not on the study of this combination – such studies have not been performed. Some of the claims surrounding phenylpiracetam, including comparisons with methylphenidate and amphetamine and comparisons based on online surveys, are not supported by peer-reviewed literature.

Product documentation

Material sheets along with batch analytical documentation are available in the category advanced nootropics. Material intended for adults.

Bibliography

1. Bobkow JG, Morozow IS, Głozman OM, Nierobkowa LN, Żmurenko ŁA. [Pharmacological characteristics of a new phenyl analog of piracetam — 4-phenylpiracetam]. Biull Eksp Biol Med. 1983;95(4):50-53. PMID: 6403074
2. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev. 1994;19(2):180-222. PMID: 8061686
3. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287-312. PMID: 20166767
4. Zvejniece L, Zvejniece B, Videja M, et al. Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. Inflammopharmacology. 2020;28(5):1283-1292. PMID: 32279140
5. Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002;8(1):70-89. PMID: 12070527
6. Johansen TH, Chaudhary A, Verdoorn TA. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors. Mol Pharmacol. 1995;48(5):946-955. PMID: 7476926
7. Tian Y, Zhang JJ, Feng SD, Zhang ZJ, Chen Y. Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers. Arzneimittelforschung. 2008;58(10):497-500. PMID: 19025058
8. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000;20(1):8-21. PMID: 10627576
9. Pepeu G, Spignoli G. Nootropic drugs and brain cholinergic mechanisms. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13 Suppl:S77-S88. PMID: 2694231
10. Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013;10(10):1070-1079. PMID: 24156263
11. Marcus L, Soileau J, Judge LW, Bellar D. Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. J Int Soc Sports Nutr. 2017;14:39. PMID: 29042830
12. Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Int J Clin Pharmacol Ther Toxicol. 1992;30(9):331-335. PMID: 1428296
13. Jędrejko K, Catlin O, Stewart T, Anderson A, Muszyńska B, Catlin DH. Unauthorized ingredients in “nootropic” dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents. Drug Test Anal. 2023;15(8):803-839. PMID: 37357012
14. Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. Neurol Clin Pract. 2021;11(3):e303-e307. PMID: 34484905